1. Trent:

This consumer lifestyle company rose 3.3% on June 24 after Chairman Noel Tata reiterated his goal to grow Trent's revenue and net profit tenfold from FY23 levels over the long term. He said that the company is just beginning its growth journey. That’s certainly one way to talk about Trent’s low market share – the company currently has only around 2% share of India’s fashion and lifestyle retail market.

Since setting the tenfold growth goal in 2023, Trent has already achieved over 2.5x revenue growth and nearly 3x profit growth. Tata said, “We are quite clear that we will not be able to reach our aspirations with only two brands. We will need many more brands, all catering to different segments of customer demand.” Trent is testing new concepts like Samoh, an ethnic wear brand, and Burnt Toast, a youth apparel brand, along with new categories like footwear, beauty and lab-grown diamonds. These are all very competitive spaces, so distribution and differentiation will be critical for Trent.

Trent had a strong FY26, with revenue rising 17.2% and net profit increasing 11.2%. Growth was led by rapid store expansion. But quick expansion carries risks. Sales at existing stores grew only in the low single digits, and new locations drove most of the growth. Trent still targets double-digit growth from existing stores. Trendlyne’s Forecaster estimates that in Q1FY27, its revenue and net profit will grow 15.8% YoY and 6.7%, respectively.

To fund its next phase, the board approved raising up to Rs 2,500 crore for warehouses, real estate, store upgrades and AI-driven supply-chain. Management is also expanding Trent’s retail footprint rapidly. It aims to grow Westside from 300 stores to 700, and scale Zudio from 960 stores to nearly 5,000 across India over the long term.

Motilal Oswal maintained its 'Buy' rating, noting improving sales at existing stores. However, the brokerage cautioned that margins will only improve significantly if existing store sales grow faster. They expect Trent’s revenue, EBITDA, and net profit to grow at annual rates of 21%, 19%, and 17% through FY27–28. 

2. Bharat Forge (BFL):

This forgings company rose 5.4% over two trading sessions after it won a Rs 425 crore order from the Ministry of Defence (MoD). Under the contract, Bharat Forge will supply gas turbine generators to power the Indian Navy's Kolkata-class warships over the next five years, marking its entry into the marine gas turbine business.

In FY26, revenue grew 11.2% to Rs 16,812 crore, led by industrial demand across power, construction & mining, and agriculture. Net profit rose 18.3%, as higher-value industrial and defence clients contributed a larger share of earnings.

Commercial vehicles contributed around one-third of Bharat Forge's export revenue in FY26, but revenue from this segment has declined 34% as truck manufacturers in North America delayed fresh orders. Management expects exports to recover as North American truck production gradually picks up.

The company's defence order book grew around 15% to nearly Rs 11,000 crore, providing a clear runway for future growth. Management said production of key defence programmes, including the ATAGS artillery system and assault rifles, will begin ramping up in the second half of FY27, with many of the orders secured last year starting to contribute to revenue.

BFL's aerospace business generated around Rs 400 crore in FY26. Vice Chairman & Joint MD Amit Kalyani sees it taking flight. “Annual revenue from the segment should comfortably cross Rs 1,000 crore over the next three years,” he said.

ICICI Securities reiterated its 'Buy' rating on the stock with a target price of Rs 2,360. The brokerage sees the company's expanding defence and aerospace businesses becoming increasingly important earnings drivers, reducing its dependence on the cyclical commercial vehicle market over time.

3. Kirloskar Oil Engines (KOEL):

This industrial machinery maker surged 20% and hit its upper circuit on June 22 after winning an order from HyperNext to supply 192 megawatts (MW) of backup power systems for data centres. The order covers 96 integrated backup power systems, one of the largest such deployments in India.

The company sold more than 50,000 diesel generator sets in FY26, with sales growing 41%, more than double the industry's 18% growth. Its market share in high-horsepower (HHP) engines has also risen from negligible levels two years ago, to nearly double digits.

In FY26, revenue grew 22% to Rs 7,701 crore, driven by demand across its power generation, industrial and international businesses. Net profit rose 18.2%, supported by higher sales of larger-capacity engines and better capacity utilisation. Gross international sales grew 37%, crossing Rs 1,000 crore.

CEO Rahul Sahai said, "We are investing Rs 1,400 crore over the next two years to add capacity for 20,000 engines, primarily for more powerful engines and international markets." The expansion is part of the company's plan to more than double annual revenue to around Rs 19,000 crore by FY30. Management expects the new capacity to generate around Rs 5,000-6,000 crore in annual revenue after the expansion is complete.

The company is also widening its power solutions portfolio beyond conventional diesel engines. KOEL said engines compatible with gas, ethanol, methanol and hydrogen blends are ready for commercial applications. It is also executing a Nuclear Power Corporation order for 10 engines of 6.3 MW each, with deliveries scheduled through 2029.

IDBI Capital retained a positive long-term view on the company, citing its leadership in HHP engines and the growing data centre opportunity. However, the brokerage downgraded the stock to 'Hold' with a higher target price of Rs 1,645 after the recent rally, saying much of the near-term growth potential is already reflected in the stock price.

4. Tata Motors (TMCV):

This commercial vehicle manufacturer surged 7% over the past week as crude prices fell after US-Iran peace talks eased tensions in the Strait of Hormuz. Lower diesel prices reduce operating costs for fleet operators and could support demand for new trucks and buses. At its Investor Day on June 23, TMCV outlined plans to increase its domestic market share from 35.7% to 40% by FY28. The bulk of that growth is expected to come from small commercial vehicles and pick-up trucks, where it has room to recover lost ground.

The company shipped over four lakh vehicles in FY26, with volumes growing 14%. However, exports accounted for just 7% of total sales volume. The €3.8 billion acquisition of Italy-based Iveco is expected to give TMCV access to an established manufacturing and distribution network across Europe, Latin America and Australia. Nomura said the acquisition “could triple combined commercial vehicle revenues over time.”

MD & CEO Girish Wagh said, “The two companies’ product portfolios and geographic footprints are largely complementary rather than overlapping”. He added that the pricing of most Iveco products begins where Tata Motors’ product range ends. Iveco’s EV and alternative fuel (natural gas, hydrogen) platforms would accelerate TMCV’s transition to zero-emission vehicles and complement its Ace EV and Starbus EV offerings in India.

Beyond vehicle sales, TMCV is expanding its digital and services business. Its Fleet Edge platform now connects more than one million vehicles, and management aims to increase that to three million over time. Although the business contributes only 16% of revenue, its higher-margin recurring nature could help diversify earnings and reduce dependence on demand cycles.

This margin focus extends beyond digital services to the core trucking business. TMCV recently announced a 2.5% price hike from July to offset higher commodity costs and expects double-digit EBITDA margins to continue in FY27. ICICI Securities reiterates its ‘Hold’ rating on the stock with a target price of Rs 450. The brokerage expects the Iveco acquisition to add significant debt to the balance sheet, a risk worth watching as the deal closes.

5. Cipla: 

This pharmaceutical stock climbed 6.2% last week after the US FDA reportedly approached the Indian Drug Manufacturers’ Association on June 23 for help with a shortage of Ifosfamide, a chemotherapy drug for testicular, bladder, and lung cancer. 

Cipla already makes the drug and holds a strong position in complex cancer treatments. If it can meet volume demands without running into compliance issues, the shortage could provide a meaningful near-term earnings boost.

A bullish note from Citi on June 22 added to the momentum. The brokerage retained a ‘Buy’ rating with a higher target price of Rs 1,700, and placed Cipla on a 90-day positive catalyst watch. Analysts expect regulatory approvals, a recovery in respiratory drug sales and new pipeline clearances to drive the stock.

The numbers support that optimism. Cipla's Nintedanib, used to treat fibrosis and cancer, now holds close to 50% of the US market. Analysts project the US business to grow 28.2% to $1 billion in FY27, with double-digit revenue growth in India as respiratory sales recover. An FDA re-inspection of the Indore plant, which carries an Official Action Indicated status for alleged manufacturing violations, could provide another catalyst once cleared.

FY26 results were a mixed bag. Revenue grew 2.2%, with new product launches lifting all markets except the US, where the absence of Lanreotide and a weaker position in Albuterol weighed on sales. Net profit fell 26.4%, hurt by rising competition for the generic cancer drug Revlimid and supply disruptions in key US products.

Cipla's margins took a hit last year after its Greece-based manufacturing partner for Lanreotide, a high-margin drug, ran into compliance issues and disrupted supplies. That pulled margins down to 15.2% in Q4. CFO Ashish Adukia expects a recovery, guiding for “EBITDA margins of 18.5% to 20% in FY27 as new launches ramp up and costs come down,” though still below 21% reported in FY26.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.